

## Current Opinion in Cardiology

### Fabry Disease: will markers of early disease enable early treatment and better outcomes?

--Manuscript Draft--

<b>Manuscript Number:</b>	HCO310416
<b>Full Title:</b>	Fabry Disease: will markers of early disease enable early treatment and better outcomes?
<b>Article Type:</b>	Review Article
<b>Corresponding Author:</b>	D Hughes London, UNITED KINGDOM
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	D Hughes
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	D Hughes
<b>Order of Authors Secondary Information:</b>	

1  
2  
3  
4  
5 **Fabry Disease: will markers of early disease enable early treatment and better**  
6 **outcomes?**  
7

8 **Derralynn A Hughes**  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19 **Lysosomal Storage Disorders Unit and Department of Haematology**  
20  
21 **Royal Free London NHS Foundation Trust and University College London**  
22  
23 **Pond St., London, UK**  
24

25  
26  
27  
28  
29  
30  
31  
32  
33 **Correspondence:**

34 Derralynn Hughes  
35  
36 Department of Haematology  
37  
38 Royal Free London NHS Foundation Trust  
39  
40 Pond St.,  
41  
42 London NW3 2QG  
43  
44 [rmgvdah@ucl.ac.uk](mailto:rmgvdah@ucl.ac.uk)  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Abstract** (200 words):

*Purpose of review:*

This review explores the clinical and pathological features of Fabry disease with particular focus on the cardiac pathology and presentation and the differences between the classical and later onset cardiac predominant forms. New modalities of imaging, biomarkers and long term treatment effects are discussed.

*Recent findings:*

Fabry disease is clinically heterogeneous and in women the clinical severity has recently been linked to skewing of X-inactivation. Two phenotypes have been described; one with early onset manifestation including pain and one with later onset single organ manifestations; however, the cardiac outcomes in these two groups appears similar. Fibrosis is found in renal and cardiac tissues on biopsy and appears to be a critical point in the pathology of Fabry disease after which response to enzyme replacement therapy is more limited. In vitro studies have suggested that lyso-globotriosylceramide may have an important role in the generation of fibrosis. Imaging including cardiac magnetic resonance imaging may have a role in detection of early stages of the disease. Long term outcomes for patients treated with enzyme replacement therapy are now being described with positive effects on renal function, cardiac architecture and clinical events with some suggestion that patients treated at earlier points in the disease course may have better outcomes.

*Summary:*

Fabry disease is a heterogeneous condition. Recent advance in understanding pathology, disease processes and treatment effects may enable future rational targeting of treatment to early disease with improved outcomes.

**Keywords:**

Fabry disease; enzyme; lysosomal storage; hypertrophy; fibrosis

**Abbreviations:**

Enzyme replacement therapy: ERT

Globotriaosylceramide: Gb3

alpha galactosidase A: GLA

Left Ventricular hypertrophy: LVH

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Glomerular Filtration Rate: GFR

Mainz severity score index: MSSI

Chronic Kidney Disease: CKD

New York Heart Association: NYHA

Cardiac magnetic resonance imaging: CMR

Electrocardiogram: ECG

## Introduction

Fabry disease (MIM 301500) is a rare X-linked lysosomal storage disorder resulting from deficiency of Alpha Galactosidase A and accumulation of its substrate globotriaosylceramide (Gb3) (1). Clinical features include pain in the extremities (acroparasthesia), sweating abnormalities, a rash (angiokeratoma) and gastrointestinal symptoms. Progression to proteinuric renal failure, cardiac hypertrophy and stroke may occur (2). The presentation is very heterogeneous affecting both males and females of all ages. Broadly, two phenotypes have been recognized an early onset classical form manifesting in childhood and a later onset form which often affects a single organ without the peripheral manifestations. However, the relationship of individual mutations to clinical presentation is not always clear and the impact of other factors on progression is unknown. Treatment is by intravenous infusion of the missing enzyme, (enzyme replacement therapy, ERT) and whilst originally described in terms of effects on surrogates such as substrate clearance on biopsy (3,4,) it has now been available for over 15 years and the long term clinical effects are emerging and new modalities of therapy are being described.

## Pathophysiology

Over 600 mutations encompassing the 7 exons of the alpha galactosidase A (GLA) gene have been described with varying effects on alpha galactosidase A enzyme activity depending on type and site of mutation (5). In addition a specific splice-site mutation (IVS4+919>A) has been found to be prevalent within the Chinese Han population (6). While the relationship between GLA mutation, reduction in enzyme activity and substrate accumulation is qualitatively clear the role of individual mutations in generation of quantitatively different levels of substrate and its derivatives in tissues and their impact on organ changes is not well understood. The accumulated sphingolipid substrate Gb3 is converted to lysos Gb3 by acid ceramidase within tissues and is detectable on biopsy of affected organs, in the

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

circulation and in the urine (7,8). Findings in an in vitro model of increased collagen production after addition of lyso Gb3 point to a critical role in the genesis of fibrosis found in heart and kidney, possibly through notch1 signalling (9). However, little lyso-Gb3 is found in the plasma of patients with some so called late onset mutations associated with relatively preserved enzyme activity despite significant single organ effects such as left ventricular hypertrophy, posterior wall fibrosis, conduction defects and ensuing morbidity (10).

## Diagnosis

Diagnosis in males is by confirmation of reduced alpha galactosidase A enzyme activity with confirmatory genotyping (11). However, in females random X-inactivation in the peripheral blood may result in non-informative enzyme activity in the normal range and a requirement for genotyping of the GLA gene to confirm the diagnosis. Measurement of Gb3 substrate and its derivatives such as lyso Gb3 and within organs, plasma and urine may be helpful in classification and assignment of pathogenicity but are not independently discriminatory for diagnosis since elevated levels have been found in patients with cardiac symptoms but without Fabry disease suggesting a possible contributory role to other conditions (12). Screening studies of patients with relatively non-specific symptoms may result in the detection of variants of unknown significance for which the pathogenic impact is unclear (13). Recent consensus initiatives have attempted to define criteria for the diagnosis of Fabry disease when the pathogenicity of a new mutation has not previously been described. Critical attributes include demonstration of low enzyme activity, relevant clinical features and ultimately demonstration of substrate accumulation in the relevant organ by biopsy where possible (14). Whilst classical and later onset forms of the condition often segregate with specific genotypes this is not absolute and each case should be individually assessed. For example while the N215S GLA mutation has been denoted a 'cardiac variant' presenting with cardiomyopathy, some patients have been described with proteinuria and renal failure (15).

Prior to diagnostic testing patients require genetic counselling and information in regard to possible future prognosis, therapy and implications of the condition for family making, employment and insurance. Pedigree analysis of an X-linked condition will be informative of genetically at risk individuals and individuals may require support in communicating the possibility of a life-limiting diagnosis to other family members (16). However, genetic screening of younger family members provides an opportunity for early diagnosis assessment and therapy of individuals who might have otherwise only come to medical attention after a detrimental event.

## Screening and prevalence

In early studies the prevalence of Fabry disease was reported to be 1 in 117 000 (Australia)(17), 1 in 468 000 (Netherlands) (18) and 1 in 833 000 (Portugal) (19); however new born screening has detected a higher incidence of GLA mutations for example 1 in 3100 newborn Italian males (20) and 1 in 1600 in Taiwan (21). The pathogenicity and natural history of all of all mutations found in newborns is unknown and there remain some ethical implications of such strategies. Screening in Taiwan has uncovered a large population of patients with a single GLA mutation resulting in a later onset cardiac predominant phenotype of Fabry disease with more immediate clinical relevance to parents and grandparents than the newborn index case (22). The screening of targeted high risk populations has informed prevalence in symptomatically enriched populations; a systematic review by Linthorst et al. of screening studies in high risk groups showed a prevalence of 0.33% in male dialysis patients, 0.1% in female dialysis patients and at least 1% for patients with left ventricular hypertrophy (23). However, the prevalence in such screening studies may be artificially inflated due to removal of patients with other diagnoses and possible misattribution of pathogenicity to polymorphisms.

## Clinical Features and classification

In the classical early onset form of the condition, males with low enzyme activity present during childhood with pain, gastrointestinal symptoms and sweating abnormalities (24). Intolerance to heat and exertion provokes painful episodes in the extremities and leads to a failure to participate in a sporting activities and pain crises at the time of febrile illnesses may prolong absence from school. Corneal opacities (cornea verticillata) and rash (angiokeratoma) in characteristic regions around the mouth, umbilicus, scrotum and hands are external features of the disease which may suggest the diagnosis (25). Proteinuria occurs in the second decade heralding decline in glomerular filtration rate and progression to end stage renal disease in a proportion of patients whilst concentric left ventricular hypertrophy and conduction abnormalities emerge subsequently. In addition to pain, neurological manifestations include hearing loss, CNS white matter lesions of unknown pathogenesis, TIA and stroke (26). Despite the X-linked inheritance females may manifest any of the clinical features of Fabry disease and whilst often of later onset and milder severity compared with males, significant clinical events including renal failure, arrhythmias and stroke are described. This finding emphasizes the importance of local enzyme activity and substrate accumulation in the tissues compared with other X-linked disorders such as haemophilia where a small percentage of normal enzyme activity may

1 function effectively within the circulation. The particularly variable severity in females is probably  
2 related to the random nature of X-inactivation with recent studies demonstrating a relationship  
3 between clinical features, enzyme activity and X-inactivation in the peripheral blood (27). Further  
4 work is required to confirm the relevance of X-inactivation in cardiac and renal tissues on local organ  
5 manifestations.  
6  
7

8  
9 More recently case finding studies aimed at patients with single organ manifestations such as renal  
10 failure, left ventricular hypertrophy and stroke have facilitated the diagnosis of patients with  
11 apparently later onset manifestations and more preserved enzyme activity (non-classical disease).  
12 Whilst diagnosis is later due to the absence of childhood suggestive symptoms such as  
13 acroparasthaesia and angiokeratoma, organ manifestations may be comparable to the classical form  
14 with similar burden of organ-specific morbidity.  
15  
16  
17  
18  
19  
20  
21

### 22 **Cardiac features**

23 Features of the cardiac involvement of Fabry disease include left ventricular hypertrophy, rarely with  
24 left ventricular outflow tract obstruction, impaired myocardial function, and progressive myocardial  
25 fibrosis, resulting in chest pain, heart failure and arrhythmias, including, on occasion, sudden cardiac  
26 death (28). Perinuclear vacuolation, intracytoplasmic whorled bodies, myocyte hypertrophy and  
27 fibrosis have been described on cardiac biopsy and at post mortem with macroscopic findings of left  
28 ventricular hypertrophy, posterior wall thinning and mild right ventricular hypertrophy. Coronary  
29 arteries are thickened without occlusion of the lumen with little atherosclerotic disease and whilst  
30 valvular abnormalities have been described they are rarely clinically significant (29).  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 ECG abnormalities, such as shortened PR interval, LVH on voltage criteria, and t wave inversion are  
41 also early findings and may precede detection of LVH on echocardiography. Pacing for atrioventricular  
42 and sinus node disease is common; QRS duration and PR interval were found to be independent  
43 predictors of future anti-bradycardia pacing (30).  
44  
45  
46

47 Risk factors most strongly associated with CV events of myocardial infarction, heart failure and death  
48 in both sexes were found to be hypertension and LVH (31). Patients with renal involvement have been  
49 found to have more severe cardiac disease. Class 5 chronic kidney disease (CKD5) was associated with  
50 worse baseline cardiac parameters and progressive LVH. LVMI increased by  $35.4 \pm 31.8 \text{ g/m}^{2.7}$  in CKD5  
51 vs  $5.7 \pm 7.9 \text{ g/m}^{2.7}$  in non-CKD5,  $p=0.044$ ) and cardiovascular events (including sudden death,  
52 arrhythmia and pacing device insertion) occurred in 100% of patients with CKD5 (21 events) compared  
53 with 26% in non-CKD5 patients (7 events) (32). However, the type of mutation does not appear to be  
54 associated with cardiac outcome. In a study of 207 consecutive patients from one cardiology clinic  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 (47% male, mean age 44 years) 28% had mutations associated with a cardiac predominant phenotype,  
2 10% developed severe heart failure (NYHA  $\geq 3$ ) 6% developed atrial fibrillation, 6% received device  
3 for bradycardia, and 3% cardiac deaths were recorded. When a composite endpoint of new onset AF,  
4 NYHA  $\geq 3$ , device insertion for bradycardia and cardiac death was considered the incidence: 2.64 per  
5 100 person-years (CI 1.78 to 3.77) did not differ between significantly between classical and cardiac  
6 variant late onset phenotypes (33). Independent predictors of outcome were the Mainz severity score  
7 index (MSSI) and QRS interval but not genotype. (33).  
8  
9

### 10 **Myocardial fibrosis: cardiac imaging and biomarkers**

11 Myocardial fibrosis, a common finding within the posterior wall at post mortem appears to correspond  
12 with posterior wall late gadolinium enhancement on cardiac magnetic resonance (CMR) imaging (34).  
13 Subjects with high annual increase in left ventricular fibrosis are at risk for sudden cardiac death. In  
14 males, fibrosis is generally detected subsequent to emergence of LVH. One study found late  
15 enhancement was not seen with end-diastolic LV wall thickness less than 12 mm (LV mass  $< 99 \text{ g/m}^2$ )  
16 and was always associated with low systolic strain rate however in females fibrosis was described prior  
17 to LVH and the severity of functional impairment was independent of LV wall thickness (35). This  
18 finding has possible implications for the timing of initiation of specific therapy since late gadolinium  
19 enhancement was associated with increased LV Mass, worse myocardial function and failure of  
20 regression with enzyme replacement therapy (36). Similarly, abnormalities on 2D speckle-tracking  
21 have been independent of LVH and in patients with normal ejection fraction. Morris et al. found  
22 principal factors linked to reduced myocardial function include LV septal wall thickness  $> 15 \text{ mm}$ , RV  
23 free wall thickness  $> 7 \text{ mm}$ , and LV longitudinal dysfunction. LV and RV fibrosis were also linked to  
24 reduced LV and RV strain and patients with reduced LV, RV, and LA strain had a worse functional class  
25 (37).  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 A recent sophistication of Fabry CMR imaging is non-contrast T-1 mapping where lipid is known to  
46 reduce the T1 parameter and was hypothesized to detect early cardiac involvement. T1 in Fabry  
47 disease appears to be discriminatory of other disorders causing LVH such as hypertension,  
48 hypertrophic cardiomyopathy and amyloid, and also to correlate inversely with left wall thickness.  
49 Low T1 may represent sphingolipid infiltration and 'pseudonormalisation' in the posterior, wall  
50 fibrosis, however correlative biopsy data is not yet available (38). Low T1 appears to occur in some  
51 patients before hypertrophy and may be a marker of early involvement and possible imaging marker  
52 of treatment effect.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Potential circulating biomarkers include both substrate and related compounds and downstream markers of pathophysiology including fibrosis. Reports are varied as to the effects of lyso-Gb3 on collagen synthesis (9,39). However, matrix metalloproteinase 9 was significantly higher in Fabry disease and correlated positively with MSS1 and negatively with endocardial fraction shortening (40). NT proBNP is a marker of diastolic dysfunction and correlated with age, creatinine, left atrial index, and abnormal ECG (41).

### **Fabry specific therapy**

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Current specific therapy for Fabry disease entails intravenous infusion of recombinant (agalsidase beta; Fabrazyme) or gene-activated (agalsidase alfa; Replagal) preparations of the deficient alpha galactosidase A. Both preparations have been available for 15 years and whilst initial demonstration of effect was based on substrate clearance on biopsy, reduction in pain and left ventricular hypertrophy (3,4) longer term clinical endpoints in patients starting early and later in the course of the disease are now being reported. A recent study of severe clinical events, renal function and cardiac structure in patients from original phase 3 clinical trials who had received agalsidase beta for ten years found 81% were free of severe clinical events (chronic dialysis, kidney transplant, myocardial infarction, congestive heart failure, major cardiac procedures, stroke and death) at ten years and survival was 94% (42). Patients classified at the outset as having low or high renal involvement had different slopes in GFR (-1.89 vs -6.82 mL/min/1.73m<sup>2</sup>/year). Similarly patients who started treatment later (over 40 years) had increases in IVST LPWT compared with those under the age of 40 who had no change in LPWT and under 30 who had no change in IVST; patients commencing therapy ≥30 years to <40 years had small increases in IVST. Further suggestion of the importance of early therapy is provided in a retrospective registry study of patients receiving agalsidase beta for 5 years where the risk of severe renal, cardiovascular and cerebrovascular clinical events during the first six months of therapy was greater in males, and patients > 40 years and in each case decreased with further time receiving enzyme replacement (43). In patients with clinical events prior to therapy the risk of further events during the first 6 months was not different to patient without events but did increase thereafter.

51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

A single centre retrospective study of patients receiving agalsidase alfa for ten years found heart failure classification had improved by at least 1 class in 22/42 patients, and angina was stable or improved in 41/42 patients. During this time no patient without LVH at baseline developed new LVH patients. In males with baseline values ≥50 g/m<sup>2.7</sup>, LVMI was significantly reduced after 10 years although in similar females whilst an early improvement was noted mean LVMI was not significantly

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

different from baseline at ten years (44). In an attempt to compare long term registry data of ERT treated patients with the natural history of untreated patients data of patients from the Fabry Outcome Survey (a Shire sponsored database) who were had received agalsidase alfa for a median of 5 years were compared with published series of untreated patients. A slower decline in renal function and slower progression of LVH was seen in patients receiving agalsidase alfa was noted and clinical events occurred later in treated patients, (16% risk of a composite morbidity event after 24 months with ERT vs 45% without treatment). (45)

### **Emerging therapies**

Recently the utility of active site specific chaperone therapy that bind and stabilise mutant protein facilitating trafficking to the lysosome has been explored. Results of three phase 2 studies of migalastat HCL (AT-1001, GR181413A, 1-deoxygalactonojirimycin), an orally bioavailable imino sugar, have been presented indicating increased activity of alpha galactosidase A and reduction of substrate in relevant tissues in vivo. (46,47) Phase 3 studies are ongoing. The use of substrate reduction therapy by inhibition of glucosyl ceramide synthase is an alternative approach to the development of an oral therapy for Fabry disease that is in early clinical development. Treating Fabry mice with compound Genz-682452 resulted in reduced tissue substrate and a delayed the onset of a deficit in thermosensory responses. The effects were most notable in young mice prior to the development of pathology (48). These products are not yet approved and remain investigational.

### **Conclusion**

After 15 years of the availability of ERT for Fabry disease long term data for the follow up of original trial cohorts and registry studies is demonstrating an effect not only on symptoms and surrogates including left ventricular mass and GFR but also on clinical events and mortality. Risk analyses indicates that patients commencing therapy at older ages and later stages of disease are less likely to have good response to therapy. This new understanding may allow the coherent use of investigations to detect early disease and direct Fabry-specific therapy to the pre-fibrotic stage of disease when outcomes might be optimised.

### **Key points:**

- Fabry disease is a rare X-linked disorder resulting in renal dysfunction, left ventricular hypertrophy and stroke.

- An early onset classical form is characterised by acroparasthaesia, angiokeratoma, sweating abnormalities and corneal whorls; a later onset form with single organ, usually cardiac manifestations is recognised.
- The pathology of cardiac and renal dysfunction appears to involve fibrosis and having occurred this appears to limit the effects of Fabry specific enzyme replacement therapy
- New imaging biomarkers such as t1 mapping may allow the detection of early stages of the disease
- Long term data on patients treated with Enzyme replacement therapy are now becoming available and point to better responses when patients are treated at an earlier stage

### **Acknowledgements**

We would like to thank the staff and patients of the Royal Free Lysosomal Storage Disorders Unit for their contribution to our studies

### **Financial support and sponsorship**

None

### **Conflicts of interest**

Dr Hughes has received research and travel grants and honoraria for speaking and advisory boards from Shire, Genzyme, Amicus and Protalix

### **References and recommended reading:**

Papers of particular interest, published within the annual period of review, (18 months/ 2015-2016) have been highlighted as:

- of special interest
- of outstanding interest

(1) Desnick RJ, Ioannou YA, Eng CM. 150:  $\alpha$ -Galactosidase A Deficiency: Fabry Disease. In: Valle D, et al., editors. The Online Metabolic and Molecular Bases of Inherited Disease [Internet] McGraw-Hill; New York: Available from:

<http://ommbid.mhmedical.com/content.aspx?bookid=474&sectionid=45374153>

(2) Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. *Nephrol Dial Transplant* 2009;**24**:2102–11.

1 (3) Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ;  
2 International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human  
3 alpha-galactosidase A--replacement therapy in Fabry's disease. *N Engl J Med*. 2001;345(1):9-16.

4 (4) Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme  
5 replacement therapy in Fabry disease: a randomized controlled trial. *JAMA*. 2001;285(21):2743-9.

6 (5) Lukas J, Scalia S, Eichler S, Pockrandt AM, Dehn N, Cozma C, Giese AK, Rolfs A. Functional and  
7 Clinical Consequences of Novel  $\alpha$ -Galactosidase A Mutations in Fabry Disease. *Hum Mutat*.  
8 2016;37(1):43-51.

9 •Important information in regard to the spectrum of effects of novel mutations

10 (6) Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, Lin SJ, Chen CH, Chiang CC, Ho HJ, Lee PC,  
11 Kao CH, Cheng KH, Hsueh C, Niu DM. High incidence of the cardiac variant of Fabry disease revealed  
12 by newborn screening in the Taiwan Chinese population. *Circ Cardiovasc Genet*. 2009;2:450-456.

13 (7) Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C,  
14 Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot  
15 RG, Hollak CE, Brady RO, Poorthuis BJ. Elevated globotriaosylsphingosine is a hallmark of Fabry  
16 disease. *Proc Natl Acad Sci U S A*. 2008;105(8):2812-7

17 (8) Ferraz MJ, Marques AR, Appelman MD, Verhoek M, Strijland A, Mirzaian M, ScheijS, Ouairy CM,  
18 Lahav D, Wisse P, Overkleeft HS, Boot RG, Aerts JM. Lysosomalglycosphingolipid catabolism by acid  
19 ceramidase: formation of glycosphingoidbases during deficiency of glycosidases. *FEBS Lett*.  
20 2016;590(6):716-25.

21 •• Insight into the mechanism of synthesis of lyso GB3 and its pathological consequences

22 (9) Sanchez-Niño MD, Carpio D, Sanz AB, Ruiz-Ortega M, Mezzano S, Ortiz A. Lyso-Gb3 activates  
23 Notch1 in human podocytes. *Hum Mol Genet*. 2015;24(20):5720-32.

24 •• Important study into potential pathological mechanism of fibrosis in Fabry

25 (10) Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ. Plasma  
26 globotriaosylsphingosine in relation to phenotypes of Fabry disease. *J Med Genet*. 2015;52(4):262-8.

27 (12) Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry  
28 disease - recommendations of a European expert group. *J Inher Metab Dis*. 2011;34(2):509-14.

29 (12) Schiffmann R, Forni S, Swift C, Brignol N, Wu X, Lockhart DJ, Blankenship D, Wang X, Grayburn  
30 PA, Taylor MR, Lowes BD, Fuller M, Benjamin ER, Sweetman L. Risk of death in heart disease is  
31 associated with elevated urinary globotriaosylceramide. *J Am Heart Assoc*. 2014;3(1):e000394.

32 •Highlights potential role of Gb3 in pathology of other disorders

33 (13) Smid BE, Hollak CE, Poorthuis BJ, van den Bergh Weerman MA, Florquin S, Kok WE, Lekanne  
34 Deprez RH, Timmermans J, Linthorst GE. Diagnostic dilemmas in Fabry disease: a case series study on  
35 GLA mutations of unknown clinical significance. *Clin Genet*. 2015;88(2):161-6.

36 (14) Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, Timmermans J,  
37 Weidemann F, West ML, Biegstraaten M, Lekanne Deprez RH, Florquin S, Postema PG, Tomberli B,  
38 van der Wal AC, van den Bergh Weerman MA, Hollak CE. Uncertain diagnosis of Fabry disease:

1 consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic  
2 variants of unknown significance. *Int J Cardiol.* 2014;177(2):400-8.

3 (15) Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme  
4 replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-  
5 blind, placebo-controlled clinical trial of agalsidase alfa. *Heart.* 2008;94(2):153-8.

6  
7 (16) Laney DA, Fernhoff PM. Diagnosis of Fabry disease via analysis of family history. *J Genet Couns.*  
8 2008;17(1):79-83.

9  
10 (17) Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. *JAMA*  
11 1999; 281: 249.

12  
13 (18) Poorthuis BJ, Wevers RA, Kleijer WJ et al: The frequency of lysosomal storage diseases in The  
14 Netherlands. *Hum Genet* 1999; 105: 151.

15  
16 (19) Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, Pinto E, Silva E, Rocha S, Marcão A,  
17 Ribeiro I, Lacerda L, Ribeiro G, Amaral O, Sá Miranda MC. Prevalence of lysosomal storage diseases in  
18 Portugal. *Eur J Hum Genet.* 2004;12(2):87-92.

19  
20 (20) Spada M, Pagliardini S, Yasuda M, Tukul T, Thiagarajan G, Sakuraba H, Ponzzone A, Desnick RJ.  
21 High incidence of later-onset Fabry disease revealed by newborn screening. *Am J Hum Genet.*  
22 2006;79(1):31-40.

23  
24 (21) Chong KW, Lu YH, Hsu JH, Lo MY, Hsiao CY, Niu DM. High incidence of cardiac variant of Fabry  
25 disease in Taiwanese revealed by newborn screening. *Taiwan Hum Genet Soc Autumn Symp.*  
26 2008;1:92-98

27  
28 (22) Liu HC, Perrin A, Hsu TR, Yang CF, Lin HY, Yu WC, Niu DM. Age at First Cardiac Symptoms in  
29 Fabry Disease: Association with a Chinese Hotspot Fabry Mutation(IVS4+919G>A), Classical Fabry  
30 Mutations, and Sex in a Taiwanese Population from the Fabry Outcome Survey (FOS). *JIMD Rep.*  
31 2015;22:107-13.

32  
33 (23) Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry  
34 disease in high-risk populations: a systematic review. *J Med Genet.* 2010;47(4):217-22.

35  
36 (24) Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-  
37 Plassmann G, Ries M, Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients  
38 in the Fabry Outcome Survey. *Eur J Clin Invest.* 2004;34(3):236-42.

39  
40 (25) van der Tol L, Cassiman D, Houge G, Janssen MC, Lachmann RH, Linthorst GE, Ramaswami U,  
41 Sommer C, Tøndel C, West ML, Weidemann F, Wijburg FA, Svarstad E, Hollak CE, Biegstraaten M.  
42 Uncertain diagnosis of Fabry disease in patients with neuropathic pain, angiokeratoma or cornea  
43 verticillata: consensus on the approach to diagnosis and follow-up. *JIMD Rep.* 2014;17:83-90.

44  
45 (26) Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry's disease. *Lancet Neurol.*  
46 2006;5(9):791-5.

47  
48 (27) Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C,  
49 De Mazancourt P, Germain DP. X-chromosome inactivation in female patients with Fabry disease.  
50 *Clin Genet.* 2016;89(1):44-54.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 (28) Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G; FOS  
2 Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry  
3 Outcome Survey. *J Med Genet.* 2009;46(8):548-52.

4 (29) Sheppard MN, Cane P, Florio R, Kavantzias N, Close L, Shah J, Lee P, Elliott P. A detailed  
5 pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on  
6 enzyme replacement therapy. *Cardiovasc Pathol.* 2010;19(5):293-301.

7  
8  
9 (30) O'Mahony C, Coats C, Cardona M, Garcia A, Calcagnino M, Murphy E, Lachmann R, Mehta A,  
10 Hughes D, Elliott PM. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-  
11 Fabry disease. *Europace.* 2011;13(12):1781-8.

12  
13 (31) Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, Strotmann J, Tallaj J, Tran TC,  
14 West ML, Beitner-Johnson D, Abiose A. Cardiovascular events in patients with Fabry disease natural  
15 history data from the Fabry registry. *J Am Coll Cardiol.* 2011;57(9):1093-9

16  
17 (32) Talbot AS, Lewis NT, Nicholls KM. Cardiovascular outcomes in Fabry disease are linked to  
18 severity of chronic kidney disease. *Heart.* 2015;101(4):287-93.

19  
20 (33) Patel V, O'Mahony C, Hughes D, Rahman MS, Coats C, Murphy E, Lachmann R, Mehta A, Elliott  
21 PM. Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease.  
22 *Heart.* 2015;101(12):961-6.

23  
24  
25 •• Evaluation of impact of various types of mutation on cardiac outcomes

26  
27 (34) Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late  
28 gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry  
29 disease. *J Cardiovasc Magn Reson.* 2006;8(3):479-82.

30  
31 (35) Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G,  
32 Wanner C, Weidemann F. Differences in Fabry cardiomyopathy between female and male patients:  
33 consequences for diagnostic assessment. *JACC Cardiovasc Imaging.* 2011;4(6):592-601.

34  
35 (36) Beer M, Weidemann F, Breunig F, Knoll A, Koeppel S, Machann W, Hahn D, Wanner C, Strotmann  
36 J, Sandstede J. Impact of enzyme replacement therapy on cardiac morphology and function and late  
37 enhancement in Fabry's cardiomyopathy. *Am J Cardiol.* 2006 5;97(10):1515-8.

38  
39 (37) Morris DA, Blaschke D, Cnaan-Kühl S, Krebs A, Knobloch G, Walter TC, Haverkamp W. Global  
40 cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular,  
41 right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status.  
42 *Int J Cardiovasc Imaging.* 2015;31(2):301-13.

43  
44 (38) Sado DM, White SK, Piechnik SK, Banyersad SM, Treibel T, Captur G, Fontana M, Maestrini V,  
45 Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC.  
46 Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance  
47 noncontrast myocardial T1 mapping. *Circ Cardiovasc Imaging.* 2013;6(3):392-8.

48  
49 (39) Choi JY, Park S. Role of protein kinase A and class II phosphatidylinositol3-kinase C2 $\beta$  in the  
50 downregulation of KCa3.1 channel synthesis and membrane surface expression by lyso-  
51 globotriaosylceramide. *Biochem Biophys Res Commun.* 2016;470(4):907-12.

52  
53 •• Alternative pathological mechanism in relation to GB3 and fibrosis compared with citation 9  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 (40) Shah JS, Hughes DA, Tayebjee MH, MacFadyen RJ, Mehta AB, Elliott PM. Extracellular matrix  
2 turnover and disease severity in Anderson-Fabry disease. *J Inher Metab Dis*. 2007;30(1):88-95.

3 (41) Coats CJ, Parisi V, Ramos M, Janagarajan K, O'Mahony C, Dawnay A, Lachmann RH, Murphy E,  
4 Mehta A, Hughes D, Elliott PM. Role of serum N-terminal pro-brain natriuretic peptide measurement  
5 in diagnosis of cardiac involvement in patients with Anderson-Fabry disease. *Am J Cardiol*.  
6 2013;111(1):111-7.

7  
8  
9 (44) Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE,  
10 Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR. Ten-year outcome of enzyme  
11 replacement therapy with agalsidase beta in patients with Fabry disease. *J Med Genet*.  
12 2015;52(5):353-8.

- 13 •• Highlights long term results of patients treated with ERT

14  
15  
16 (43) Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart  
17 A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG.  
18 Time to treatment benefit for adult patients with Fabry disease receiving agalsidase  $\beta$ : data from the  
19 Fabry Registry. *J Med Genet*. 2016 Mar 18. pii: jmedgenet-2015-103486.

20  
21  
22 (44) Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry  
23 disease: cardiac outcomes after 10 years' treatment. *Orphanet J Rare Dis*. 2015;10:125.

- 24 •• Highlights long term results of patients treated with ERT

25  
26  
27 (45) Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G, Ramaswami U, West M,  
28 Wijatyk A, Giugliani R; Fabry Outcome Survey Study Group. Long-term effectiveness of agalsidase  
29 alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. *Mol Genet Metab Rep*.  
30 2015;3:21-7.

31  
32  
33 (46) Giugliani R, Waldek S, Germain DP, Nicholls K, Bichet DG, Simosky JK, Bragat AC, Castelli JP,  
34 Benjamin ER, Boudes PF. A Phase 2 study of migalastat hydrochloride in females with Fabry disease:  
35 selection of population, safety and pharmacodynamic effects. *Mol Genet Metab*. 2013;109(1):86-92.

36  
37  
38 (47) Germain DP, Giugliani R, Hughes DA, Mehta A, Nicholls K, Barisoni L, Jennette CJ, Bragat A,  
39 Castelli J, Sitaraman S, Lockhart DJ, Boudes PF. Safety and pharmacodynamic effects of a  
40 pharmacological chaperone on  $\alpha$ -galactosidase activity and globotriaosylceramide clearance in Fabry  
41 disease: report from two phase 2 clinical studies. *Orphanet J Rare Dis*. 2012;7:91.

42  
43  
44 (48) Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, Desnick RJ, Scheule RK,  
45 Leonard JP, Cheng SH, Marshall J. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel  
46 Antagonist of Glucosylceramide Synthase for Fabry Disease. *Mol Med*. 2015;21:389-99.

47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**EDITORIAL MANAGER - MS CHECK FORM**

MS Number	HCO310416
Corresponding Author name	Derralynn Hughes
Review title	<b>Fabry Disease: will markers of early disease enable early therapy and better outcomes?</b>
Section	Lipids and Emerging risk factors
Author address on MS?	Y
Author phone number?	N
Author email (if not on MS)	Y

Structured abstract	Y
Key words (max. 5)	Y
Introduction	Y
Headings in text	Y
Conclusion	Y
Key points box	Y

Word count: abstract	239
Word count: text	2762

Bullets and annotations/ within RP?	Y
Refs. in sequence?	Y
Acknowledgements; Financial support and sponsorship; Conflicts of interest.	Y/Y/Y

*Vancouver references?/Page numbers*

# Colour figures	-	
# Half tones	-	
# Line drawings	-	
# Tables	-	
Supplementary Digital Content	-	
Figures/Tables cited in text?		
Figure legends AND titles?		
Figures to be printed in colour?		

Comments for <b>copyeditor</b> :
----------------------------------